FindTrial
Sign In

mechanisms of endothelial disfunction in patients with les: role of TNF- Alpha

mechanisms of endothelial disfunction in patients with les: role of TNF- Alpha

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-000499-41-IT
Enrollment
Unknown
Registered
2007-06-28
Start date
2004-12-10
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lupus (SLE) MedDRA version: 6.1 Level: SOC Classification code 10021428

Interventions

Trade Name: REMICADE*EV F 100MG+F 2ML Pharmaceutical Form: Solution for injection INN or Proposed INN: Infliximab CAS Number: 170277-31-3 Concentration unit: mg milligram(s) Concentration type: equal

Sponsors

POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026